<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39344109</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2287-4208</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Aug</Month><Day>02</Day></PubDate></JournalIssue><Title>The world journal of men's health</Title><ISOAbbreviation>World J Mens Health</ISOAbbreviation></Journal><ArticleTitle>Long Term Cardiovascular Safety of Testosterone Therapy: A Review of the TRAVERSE Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.5534/wjmh.240081</ELocationID><Abstract><AbstractText>TRAVERSE (TheRapy for Assessment of long-term Vascular events and Efficacy ResponSE in hypogonadal men) is multicentre randomized, double-blind, placebo-controlled, noninferiority trial of testosterone therapy, enrolling 5,246 men 45 to 80 years of age who had pre-existing or a high risk of cardiovascular disease and who reported symptoms of hypogonadism. Subjects required two fasting testosterone levels of less than 10.4 nmol/L. Patients were randomly assigned to receive daily transdermal 1.62% testosterone gel (dose adjusted to maintain testosterone levels between 12 nmol/L and 26 nmol/L) or placebo gel for a mean 27.1 months. The primary cardiovascular safety end point was the first occurrence of any component of a composite of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke, assessed in a time-to-event analysis. TRAVERSE found no increase in major adverse cardiac events or prostate related events, including prostate cancer, effectively addressing the concerns raised by the United States Food and Drug Administration.</AbstractText><CopyrightInformation>Copyright Â© 2024 Korean Society for Sexual Medicine and Andrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hackett</LastName><ForeName>Geoffrey Ian</ForeName><Initials>GI</Initials><Identifier Source="ORCID">0000-0003-2073-3001</Identifier><AffiliationInfo><Affiliation>Department of Urology and Sexual Medicine, Spire Hospital, Sutton Coldfield, UK. hackettgeoff@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>World J Mens Health</MedlineTA><NlmUniqueID>101596899</NlmUniqueID><ISSNLinking>2287-4208</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hypogonadism</Keyword><Keyword MajorTopicYN="N">Prostatic neoplasms</Keyword><Keyword MajorTopicYN="N">Sexual dysfunction</Keyword><Keyword MajorTopicYN="N">Testosterone therapy</Keyword></KeywordList><CoiStatement>The authors have nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39344109</ArticleId><ArticleId IdType="doi">10.5534/wjmh.240081</ArticleId><ArticleId IdType="pii">42.e71</ArticleId></ArticleIdList></PubmedData></PubmedArticle>